752 related articles for article (PubMed ID: 26807719)
1. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
[TBL] [Abstract][Full Text] [Related]
2. Early Treatment with Empagliflozin and GABA Improves
Daems C; Welsch S; Boughaleb H; Vanderroost J; Robert A; Sokal E; Lysy PA
J Diabetes Res; 2019; 2019():2813489. PubMed ID: 31467926
[TBL] [Abstract][Full Text] [Related]
3. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
[TBL] [Abstract][Full Text] [Related]
4. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Steven S; Oelze M; Hanf A; Kröller-Schön S; Kashani F; Roohani S; Welschof P; Kopp M; Gödtel-Armbrust U; Xia N; Li H; Schulz E; Lackner KJ; Wojnowski L; Bottari SP; Wenzel P; Mayoux E; Münzel T; Daiber A
Redox Biol; 2017 Oct; 13():370-385. PubMed ID: 28667906
[TBL] [Abstract][Full Text] [Related]
5. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
[TBL] [Abstract][Full Text] [Related]
6. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.
Hansen HH; Jelsing J; Hansen CF; Hansen G; Vrang N; Mark M; Klein T; Mayoux E
J Pharmacol Exp Ther; 2014 Sep; 350(3):657-64. PubMed ID: 24993361
[TBL] [Abstract][Full Text] [Related]
7. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
Hogan MF; Hackney DJ; Aplin AC; Mundinger TO; Larmore MJ; Castillo JJ; Esser N; Zraika S; Hull RL
J Endocrinol; 2021 Feb; 248(2):95-106. PubMed ID: 33337344
[TBL] [Abstract][Full Text] [Related]
8. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
Lamos EM; Younk LM; Davis SN
Expert Opin Investig Drugs; 2014 Jun; 23(6):875-82. PubMed ID: 24746173
[TBL] [Abstract][Full Text] [Related]
10. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
[TBL] [Abstract][Full Text] [Related]
12. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats.
Takeshige Y; Fujisawa Y; Rahman A; Kittikulsuth W; Nakano D; Mori H; Masaki T; Ohmori K; Kohno M; Ogata H; Nishiyama A
Hypertens Res; 2016 Jun; 39(6):415-22. PubMed ID: 26818652
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.
Michel MC; Mayoux E; Vallon V
Naunyn Schmiedebergs Arch Pharmacol; 2015 Aug; 388(8):801-16. PubMed ID: 26108304
[TBL] [Abstract][Full Text] [Related]
16. Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
Fushimi Y; Obata A; Sanada J; Nogami Y; Ikeda T; Yamasaki Y; Obata Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Sci Rep; 2021 Aug; 11(1):16120. PubMed ID: 34373487
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Dixit D; Yoon Y; Volino LR; Mansukhani RP
Am J Health Syst Pharm; 2015 Nov; 72(22):1943-54. PubMed ID: 26541949
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
Luippold G; Klein T; Mark M; Grempler R
Diabetes Obes Metab; 2012 Jul; 14(7):601-7. PubMed ID: 22268612
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus.
Al Jobori H; Daniele G; Adams J; Cersosimo E; Solis-Herrera C; Triplitt C; DeFronzo RA; Abdul-Ghani M
J Clin Endocrinol Metab; 2018 Apr; 103(4):1402-1407. PubMed ID: 29342295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
